Modified amino acid for the inhibition of platelet aggregation

Abstract

A method of inhibiting blood platelet aggregation in a mammal is provided. The method comprises the administration of a platelet aggregation inhibiting amount of a modified amino acid or pharmaceutically acceptable salt thereof.

1 : A method of inhibiting platelet aggregation in a mammal comprising administering to said mammal a pharmaceutical composition comprising a modified amino acid, or a pharmaceutically acceptable salt thereof. 
     
     
         2 : The method according to  claim 1 , wherein the pharmaceutical composition additionally comprises a pharmacologically active agents, and wherein the modified amino acid or salt thereof is present in an amount effective to inhibit platelet aggregation. 
     
     
         3 : The method according to  claim 1 , wherein the modified amino acid is N-(−5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC). 
     
     
         4 : The method according to  claim 2 , wherein the pharmacologically active agent comprises heparin, insulin, parathyroid hormone or calcitonin. 
     
     
         5 : The method according to  claim 4 , wherein the mammal is human and the calcitonin is salmon calcitonin. 
     
     
         6 : The method according to  claim 1  wherein the modified amino acid or pharmaceutically acceptable salt thereof is present in an amount of about 25 mg to about 400 mg. 
     
     
         7 : The method according to  claim 6 , wherein the modified amino acid or pharmaceutically acceptable salt thereof is present in an amount of about 100 mg to about 200 mg. 
     
     
         8 : The method according to  claim 2 , wherein the pharmacologically active agent is present in an amount of 0.05% to 70% by weight relative to the total weight of the pharmaceutical composition. 
     
     
         9 : The method according to  claim 2 , wherein the pharmaceutical composition comprises calcitonin and 5-CNAC or a pharmaceutically acceptable salt thereof. 
     
     
         10 : A pharmaceutical composition comprising a platelet aggregation inhibiting amount of a modified amino acid, or a pharmaceutically acceptable salt thereof. 
     
     
         11 : The pharmaceutical composition according to  claim 10 , further comprising a pharmacologically active agent, wherein the modified amino acid or salt thereof is present in an amount effective to inhibit platelet aggregation. 
     
     
         12 - 13 . (canceled)